3-6 July 2013

Barcelona, Spain

Scientific Agenda

Wednesday, 3 July, 2013

12:30

Expert discussion (by invitation only): Rectal cancer with synchronous metastases
Scientific committee and selected experts

Session I: Presentation of selected abstracts I

Chairs:Eric Van Cutsem, MD, PhD, Mario Dicato, MD, and Josep Tabernero, MD, PhD

15:00

Welcome and introduction: Congress chairs
Eric Van Cutsem, MD, PhD, Mario Dicato, MD, and Josep Tabernero, MD, PhD

15:05

Presentation of selected abstracts on pancreatic cancer

P-ERK, P-AKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: A translational subgroup analysis from AIO-PK0104
S. Boeck, et al., O-0003

Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer after ≥ 2 prior therapies
E. Mitchell, et al., O-0004

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: Results of an AGEO multicenter prospective study
L. Marthey, et al., O-0002

Phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Influence of prognostic factors on survival
J. Tabernero, et al., O-0001

15:45

Keynote lecture 1: The MET oncogene: From molecular biology to clinical trials
Paolo M. Comoglio, MD, PhD

Session II: Cancer of the pancreas and bile ducts

Chairs: Andrés Cervantes, MD, PhD and Margaret A. Tempero, MD

16:15

Understanding risk for pancreatic cancer 
Margaret A. Tempero, MD

16:35

The optimal algorithm for diagnosis and for obtaining a biopsy in pancreatic cancer 
Pascal Hammel, MD, PhD

16:55

ESMO/ESDO Guideline Session I: Interactive session on pancreatic cancer guidelines

Introduction 
Andrés Cervantes, MD, PhD

17:00

Clinical case presentation on pancreatic cancer: Metastatic disease and locally advanced disease 
Pieter-Jan Cuyle, MD

17:15

Clinical case discussion
Thomas Seufferlein, MD, PhD

17:30

Clinical case presentation on pancreatic cancer: Adjuvant treatment 
Noelia Tarazona Llavero, MD

17:40

Clinical case discussion
Christophe Louvet, MD, PhD

17:55

Presentation of selected abstract

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study
P. Hammel, et al.

18:05

Expert view: Gemcitabine monotherapy vs. doublet therapy vs. FOLFIRINOX for metastatic pancreatic adenocarcinoma
Jordan D. Berlin, MD

18:25

New agents on the horizon in pancreatic cancer 
Michel Ducreux, MD, PhD

18:45

Should patients with resected bile duct cancer receive an adjuvant treatment? 
Juan W. Valle, MD

19:10

ESO Cancer Observatory begins

20:40

ESO Cancer Observatory adjourns

20:40

15th Anniversary Welcome Reception

Thursday, 4 July 2013

Session III: Meet the expert concurrent presentations

8:00

Anal cancer
Robert Glynne-Jones, MBBS, FRCR, FRCP and Karin Haustermans, MD, PhD

Cholangiocarcinoma and gall bladder cancer
Thomas Gruenberger, MD and Juan W. Valle, MD

Thrombosis in GI cancer (including novel anticoagulants)
Mario Dicato, MD

GIST
John R. Zalcberg, MD, PhD, FRACP

Challenges and limitation in rectal cancer management
Chris Cunningham, MD, FRCSEd and Andre D’Hoore, MD, PhD

How can I learn medical writing?
Daniel G. Haller, MD

9:00

Session adjourns

Session IV: Cancer of the liver

Chairs: Josep M. Llovet, MD and Philippe Rougier, MD, PhD

9:00

Pathologic and molecular changes occurring in HCC
Josep M. Llovet, MD

9:20

ESMO/ESDO Guideline Session II: Interactive session on hepatocellular cancer guidelines

Clinical case presentation on hepatocellular cancer
Joseph Weber, MD

9:40

Clinical case discussion
Chris Verslype, MD, PhD

9:50

How to decide in the jungle of local/regional therapies for HCC?
Chris Verslype, MD, PhD

10:10

New agents on the horizon in HCC
Augusto Villanueva, MD

10:30

Break and poster viewing:
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session V: Rare tumors: Neuroendocrine tumors and gastrointestinal stromal tumors

Chairs: Jean-Yves Blay, MD, PhD and John R. Zalcberg, MD, PhD, FRACP

10:55

Recommendations for the management of pancreatic NET
Jaume Capdevila, MD

11:15

Recommendations for the management of appendiceal NET
Ulrich-Frank Pape, MD

11:30

Recommendations for the management of rectal NET
Dermot O'Toole, MD

11:45

Presentation of selected abstracts

Peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow up on 450 patients
S. Ezziddin, et al., O-0005

Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET: A lesion-by-lesion analysis in PRRT-patients
S. Van Binnebeek, et al., O-0006

12:05

Efficacy and toxicity of peptide receptor targeted radiopeptide therapy
Dik J.Kwekkeboom, MD

12:25

Relevance of molecular markers for management of GIST tumors
Jean-Yves Blay, MD, PhD

12:45

Session adjourns

13:00

Concurrent luncheon symposia begin

14:30

Concurrent luncheon symposia adjourn

Session VI: Esophageal cancer

Chairs: David Cunningham, MD, FRCP and Arnaud Roth, MD

14:45

The clinical value of distinguishing SCCC and adenocarcinoma and lower third versus GEJ cancer
Prateek Sharma, MD

15:05

Treatment of Barrett's esophagus: Update on new endoscopic modalities
Raf Bisschops, MD

15:25

Debate: Which neoadjuvant treatment in GEJ?

Pro chemotherapy
David Cunningham, MD, FRCP

Pro chemoradiotherapy
Michael Stahl, MD

15:50

Discussion and cases
Moderator: Arnaud D. Roth, MD
Panel: David Cunningham, MD, FRCP, Arnulf H. Hölscher MD, FACS, FRCS, and Michael Stahl, MD

16:10

Travel grant award ceremony

16:15

Break and poster viewing:
Clinical/basic non-CRC abstracts

Session VII: Gastric cancer

Chairs: Enrique Aranda, MD, PhD and Daniel G. Haller, MD

16:45

'Pathology' of gastric cancer
Fatima Carneiro, MD, PhD

17:05

Challenges in the surgical management of gastric cancer
Arnulf H. Hölscher MD, FACS, FRCS

17:25

Presentation of selected abstracts

Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: Final results from the CLASSIC trial
S.H. Noh, et al., O-0007

17:35

Should all patients be treated with adjuvant and/or neoadjuvant treatment?
Philippe Rougier, MD, PhD

17:50

What is the reference cytotoxic regimen in advanced gastric cancer?
Andrés Cervantes, MD, PhD

18:05

Presentation of selected abstracts

REGARD Phase 3, randomized trial of ramucirumab in patients with metastatic gastric or GEJ adenocarcinoma following progression on first-line chemotherapy
J. Tabernero, et al., O-0008

18:15

Case presentation and discussion: Second-line therapy in gastric cancer
Maria Alsina, MD

18:30

Targeted agents in gastric cancer
Yung-Jun Bang, MD

18:45

Session adjourns

19:00

Evening symposium begins

20:30

Evening symposium adjourns

Friday, 5 July 2013

Session VIII: Meet the expert concurrent presentations

Parallel with Session IX: Presentation of selected abstracts IIA, Session IX: Presentation of selected abstracts IIB, and Session X: ESMO session: Focus on young medical oncologist

8:00

Peritoneal metastases: Challenges for the surgeon
Marcello Deraco, MD

Carcinoma of unknown origin
Nicholas A. Pavlidis, MD, PhD, FRCP

Treatment of elderly patients with GI cancer
Demetris Papamichael, MD

Liver metastases
René Adam, MD and Thomas Gruenberger, MD

9:00

Session adjourns

Session IX: Presentation of selected abstracts IIA

Parallel with Session VIII: Meet the expert concurrent presentations Session IX: Presentation of selected abstracts IIB, and Session X: ESMO session: Focus on young medical oncologist

8:00

Presentation of selected abstracts

Nanofluidic digital PCR for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies
D. Azuara, et al., O-0011

Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC113
U. Mansmann, et al., O-0009

Long-survivors with lung metastases and KRAS mutations have an increased risk to develop brain metastases from colorectal cancer
F. Zoratto, et al., O-0010

KRAS/NRAS mutations in PEAK: a randomized phase 2 study of 1st-line treatment with FOLFOX6 + panitumumab or bevacizumab for wild-type KRAS mCRC
F. Rivera, et al., O-0013

Mutation in KRAS codon 13, but not in codon 12, correlates with poor prognosis in colorectal cancer: A cohort study
S. Wangefjord, et al., O-0016

8:50

Abstract Discussion: Back to the future: KRAS and beyond and don't forget response
Heinz-Josef Lenz, MD

9:00

Presentation of selected abstracts

Updated results of the phase 2 IMPACT trial: Maintenance with MGN1703 vs placebo in patients with advanced colorectal carcincoma (mCRC)
H.J. Schmoll, et al., O-0012

SPIRITT (study 20060141): a randomized phase 2 study of 2nd-line treatment with FOLFIRI + panitumumab or bevacizumab for wild-type KRAS mCRC
B. Piperdi, et al., O-0015

Observed Benefit of aflibercept in mCRC patients ≥65 Years Old: Results of a prespecified age-based analysis of the VELOUR Study
P. Ruff, et al., O-0017

Intraoperative radiotherapy reduces local recurrence rates in patients with locally advanced rectal cancer with microscopically involved circumferential resection margins
W. Alberda, et al., O-0014

Chronicle: A phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine/oxaliplatin versus control
R. Glynne-Jones, et al., O-0018

9:50

Abstract discussion
Paulo M. Hoff, MD

10:00

Session adjourns

Session IX: Presentation of selected abstracts IIB

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX: Presentation of selected abstracts IIA and Session X: ESMO session: Focus on young medical oncologist

8:00

Presentation of selected abstracts

Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study
W. Wulaningsih, et al., O-0019

Socio-economic and geographical disparities in colorectal adenomas and colorectal cancers detection: A population-based study
I. Fournel, et al., O-0020

8:20

Abstract discussion: Risk factors for GI malignancies
Nadir Arber, MD, MSc, MHA

8:30

Presentation of selected abstracts

Pertuzumab pharmacokinetics and safety in combination with trastuzumab and chemotherapy in patients with HER2-positive advanced gastric cancer (aGC)
Y.K. Kang, et al., O-0021

Comparison of docetaxel, fluorouracil and oxaliplatin or cisplatin with other modified schedules: a new therapeutic index in advanced gastric cancer
S. Pernot, et al., O-0022

8:50

Abstract discussion
Alfredo Carrato, MD, PhD

10:00

Session adjourns

Session X: ESMO session: Focus on young medical oncologist

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX: Presentation of selected abstracts IIA and Session IX: Presentation of selected abstracts IIB

Chairs: Roberto Labianca, MD and Erika Martinelli, MD, PhD

8:00

Why invest in Young Medical Oncologists?
Jean-Yves Douillard, MD, PhD

8:10

Use of preclinical platform for personalized treatment in CRC
Teresa Troiani, MD

8:30

The impact on our clinical practice after the drug approval of new targeted agents in mCRC
Camilla Qvortrup, MD

8:45

Beyond EGFR and VEGFR inhibitors: Targeting the RAS/RAF/MEK and alternative pathway in CRC
Erika Martinelli, MD, PhD

8:55

ESMO Young Oncologist Committee Presentation
Erika Martinelli, MD, PhD

Session XI: Clinical trials for GI oncologists - Trials and endpoints in GI cancer

Parallel with Session XII: Special EONS nurses' symposium: Management of patients with rectal cancer

Chairs: Aimery de Gramont, MD, PhD and Axel Grothey, MD

9:00

How to balance regulations and clinical practice
Francesco Pignatti, MD

9:15

Magnitude of benefit (delta and HRs)
Alberto Sobrero, MD

9:30

Pharmacodynamic endpoints
Johanna C. Bendell, MD

9:45

Relevance of new data: Early tumor shrinkage
Volker Heinemann, MD, PhD

10:00

Functional imaging with MRI
Thomas C. Lauenstein, MD

10:15

Discussion

10:30

Break and poster viewing: Clinical/basic CRC abstracts

Session XII: Special EONS nurses' symposium: Management of patients with rectal cancer

Parallel with Session XI: Clinical trials for GI oncologist - Trials and endpoints in GI Cancer

Chair: Sultan Kav, RN, PhD

9:00

Improving adherence to oral agents for colorectal cancer treatment
Sultan Kav, RN, PhD

9:20

Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy
Alessandra Milani, RN

9:40

Nurse-led care for the management of side effects of pelvic radiotherapy
Gail Dunberger, RN, PhD

10:00

The role of patients groups and advocacy groups in colon cancer
Jola Goore Booth

10:20

Discussion

10:30

Break and poster viewing: Clinical/basic CRC abstracts

Session XIII: Multimodality therapy for rectal cancer

Chairs: Michel Ducreux, MD, PhD and Karin Haustermans, MD, PhD

11:00

Imaging in rectal cancer: What is mandatory for optimal staging?
Geerard L Beets, MD, PhD

11:20

Can the pathologist judge the quality of rectal cancer surgery and treatment?
Nicholas West, MD, BSc, PhD, ChB

11:35

Organ sparing-surgery in rectal cancer: How important is it? How can we progress with it?
Chris Cunningham, MD, FRCSEd

11:55

Presentation of selected abstract

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: Response to the local treatment after chemoradiation and surgery as secondary endpoint.
H.J. Schmoll, et al., O-0023

12:05

Which neoadjuvant chemoradiotherapy regimen in rectal cancer?
Karin Haustermans, MD, PhD

12:20

Presentation of selected abstract

Preoperative bevacizumab, capecitabine and oxaliplatin (CAPOX-B) in intermediate risk rectal adenocarcinoma, selected by high resolution MRI. GEMCAD 0801 study
F.M. Carlos, et al., O-0024

12:30

When is neoadjuvant chemotherapy (without radiotherapy) an option?
David Cunningham, MD, FRCP

12:45

Rectal cancer: What is next in the field of radiotherapy?
Vicenzo Valentini, MD

13:00

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

Session XIV: Highlights in cancer

Chairs: Mario Dicato, MD and Josep Tabernero, MD, PhD

15:00

Keynote lecture 2:Molecular changes in pancreatic cancer
David A. Tuveson, MD, PhD

15:30

Keynote lecture 3: Carcinogenesis and molecular events in gastric cancer
Fatima Carneiro, MD, PhD

16:00

Keynote lecture 4:Liquid biopsies to monitor response and resistance to targeted therapies
Alberto Bardelli, MD

16:30

Break and poster viewing:
Abstracts to be presented: Clinical/basic CRC abstracts

Session XV: Liver and peritoneal liver metastases

Chairs: David Cunningham, MD, FRCP and Bernard Nordlinger, MD

17:00

Presentation of selected abstracts

Randomised, phase 2 study (OLIVIA) of bevacizumab plus mFOLFOX6 or FOLFOXIRI in patients with initially unresectable colorectal cancer liver metastases
R. Adam, et al., O-0025

FOLFOXIRI/bevacizumab versus FOLFIRI/bevacizumab as first-line treatment in unresectable metastatic colorectal cancer: Results of phase III TRIBE trial by GONO group
C. Cremolini, et al., O-0026

17:20

Surgery for liver metastases: How far should and can the surgeon go? Recommendations from an expert panel
René Adam, MD

17:40

The multimodal treatment of liver metastases: Frequently asked questions
Bernard Nordlinger, MD

18:00

Multidisciplinary management of peritoneal carcinomatosis from colorectal cancer: New perspectives
Andre D'Hoore, MD, PhD

18:20

Liver directed therapy — When and how?
Geert Maleux, MD, PhD

Session XVI: Poster discussion session

18:40

Poster discussion session I on biomarkers (PD-0001 - PD-0011, PD-0035)
Mario Dicato, MD

18:50

Poster discussion session II on surgery (PD-0012 - PD-0018)
Bernard Nordlinger, MD

19:00

Poster discussion session III on clinical non-colon cancer (PD-0019 - PD-0023)
Enrique Aranda, MD, PhD

19:10

Poster discussion on clinical colorectal cancer (PD- 0024 - PD-0034)
Richard M. Goldberg, MD

19:20

Session adjourns

Saturday, 6 July 2013

Session XVII: Highlights in CRC

Chairs: Nadir Arber, MD, MSc, MHA and Thomas Seufferlein, MD, PhD

8:25

Hereditary colon cancer syndromes
Judith Balmaña, MD, PhD

8:45

Keynote lecture 5: Screening for CRC in 2013
C. Richard Boland, MD

9:15

Personalized aspirin and NSAID therapy in colorectal cancer prevention
Nadir Arber, MD, MSc, MHA

9:35

Break

Session XVIII: Metastatic colorectal cancer

Chairs: Richard M. Goldberg, MD and Eric Van Cutsem, MD, PhD

10:05

What is the best cytotoxic backbone for biologicals?
Dirk Arnold, MD

10:25

Presentation of selected abstracts

Bevacizumab beyond progression in metastatic colorectal cancer patients receiving a first-line treatment containing bevacizumab: Update of BEBYP trial by GONO
L. Salvatore, et al., O-0027

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A phase 3 non-inferiority trial
D. Koeberle, et al., O-0028

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)
D. Modest, et al., O-0029

10:55

Abstract discussion: Induction and maintenance therapy of advanced CRC
Alberto Sobrero, MD

11:05

Presentation of selected abstracts

Results according to age in AVEX, a randomized phase 3 trial of bevacizumab with capecitabine for elderly patients with mCRC
M. Sanders, et al., O-0030

Evaluation of KRAS, NRAS, and BRAF mutations in PRIME: Panitumumab with FOLFOX4 as first-line treatment in metastatic colorectal cancer (mCRC)
J.Y. Douillard, et al., O-0031

Phase III Randomized, placebo(PL)-Controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study
A. Grothey, et al., O-0032

11:35

Abstract discussion: Subsets of patients with colorectal cancer -Who benefits and who does not?
Alan P. Venook, MD

11:45

Which biological targeted agent and for whom?
Axel Grothey, MD

12:05

Molecular markers beyond KRAS for anti-EGFR targeted agents — What is new?
Heinz-Josef Lenz, MD

12:25

Maintenance treatment or stop and go: What is the standard?
Roberto Labianca, MD

12:45

Session adjourns

13:00

Concurrent luncheon symposia begin

14:30

Concurrent luncheon symposia adjourn

Session XIX: Hot topics in colon cancer

Chairs: Fortunato Ciardiello, MD, PhD and Mario Dicato, MD

14:45

New drugs and targets in colorectal cancer gastrointestinal cancer
Josep Tabernero, MD, PhD

15:05

Are we making progress in the molecular taxonomy of colon cancer?
Sabine Tejpar, MD, PhD

15:25

Should MSI be determined in all patients with stage II and III colon cancer patients?
Julien Taieb, MD, PhD

15:45

How to treat a patient with stage III colon cancer in 2013
Aimery de Gramont, MD, PhD

Session XX: Report on expert discussion

16:05

Presentation of outcome of expert discussion: Rectal cancer with synchronous metastases
Eric Van Cutsem, MD, PhD, Mario Dicato, MD and Josep Tabernero, MD, PhD

16:30

Adjourn